201 related articles for article (PubMed ID: 24849143)
1. Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy.
Norum JH; Andersen K; Sørlie T
Br J Surg; 2014 Jul; 101(8):925-38. PubMed ID: 24849143
[TBL] [Abstract][Full Text] [Related]
2. Exploring novel targets of basal-like breast carcinoma by comparative gene profiling and mechanism analysis.
Wu YM; Hu W; Wang Y; Wang N; Gao L; Chen ZZ; Zheng WQ
Breast Cancer Res Treat; 2013 Aug; 141(1):23-32. PubMed ID: 23933801
[TBL] [Abstract][Full Text] [Related]
3. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?
Brenton JD; Carey LA; Ahmed AA; Caldas C
J Clin Oncol; 2005 Oct; 23(29):7350-60. PubMed ID: 16145060
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumour cells: insights into tumour heterogeneity.
Hayes DF; Paoletti C
J Intern Med; 2013 Aug; 274(2):137-43. PubMed ID: 23844916
[TBL] [Abstract][Full Text] [Related]
5. [Are the new breast cancer subtypes (luminal A, B etc.) of practical impact? Yes].
Stöger H
Dtsch Med Wochenschr; 2013 Oct; 138(41):2096. PubMed ID: 24085364
[No Abstract] [Full Text] [Related]
6. A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX.
Kaklamani V
Expert Rev Mol Diagn; 2006 Nov; 6(6):803-9. PubMed ID: 17140367
[TBL] [Abstract][Full Text] [Related]
7. [Are the new breast cancer subtypes (luminal A, B etc.) of practical impact? No].
Gampenrieder SP
Dtsch Med Wochenschr; 2013 Oct; 138(41):2097. PubMed ID: 24085365
[No Abstract] [Full Text] [Related]
8. Using molecular profiles to tailor treatment in breast cancer: are they ready for prime time?
Peintinger F
Curr Opin Obstet Gynecol; 2014 Feb; 26(1):21-6. PubMed ID: 24346126
[TBL] [Abstract][Full Text] [Related]
9. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
10. Mixture classification model based on clinical markers for breast cancer prognosis.
Zeng T; Liu J
Artif Intell Med; 2010; 48(2-3):129-37. PubMed ID: 20005686
[TBL] [Abstract][Full Text] [Related]
11. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L
Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420
[TBL] [Abstract][Full Text] [Related]
12. How to best classify breast cancer: conventional and novel classifications (review).
Charafe-Jauffret E; Ginestier C; Monville F; Fekairi S; Jacquemier J; Birnbaum D; Bertucci F
Int J Oncol; 2005 Nov; 27(5):1307-13. PubMed ID: 16211226
[TBL] [Abstract][Full Text] [Related]
13. Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy.
Andre F; Pusztai L
Nat Clin Pract Oncol; 2006 Nov; 3(11):621-32. PubMed ID: 17080180
[TBL] [Abstract][Full Text] [Related]
14. Prognostic applications of gene expression signatures in breast cancer.
Normanno N; De Luca A; Carotenuto P; Lamura L; Oliva I; D'Alessio A
Oncology; 2009; 77 Suppl 1():2-8. PubMed ID: 20130425
[TBL] [Abstract][Full Text] [Related]
15. Molecular and clinicopathological markers of prognosis in breast cancer.
Boyle DP; McCourt CM; Matchett KB; Salto-Tellez M
Expert Rev Mol Diagn; 2013 Jun; 13(5):481-98. PubMed ID: 23782255
[TBL] [Abstract][Full Text] [Related]
16. Advances in molecular and clinical subtyping of breast cancer and their implications for therapy.
Cadoo KA; Traina TA; King TA
Surg Oncol Clin N Am; 2013 Oct; 22(4):823-40. PubMed ID: 24012401
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy.
Huber KE; Carey LA; Wazer DE
Semin Radiat Oncol; 2009 Oct; 19(4):204-10. PubMed ID: 19732684
[TBL] [Abstract][Full Text] [Related]
18. Partial breast irradiation: targeting volume or breast molecular subtypes?
Orecchia R; Leonardi MC
Breast; 2013 Aug; 22 Suppl 2():S137-40. PubMed ID: 24074774
[TBL] [Abstract][Full Text] [Related]
19. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition.
Mamessier E; Sylvain A; Bertucci F; Castellano R; Finetti P; Houvenaeghel G; Charaffe-Jaufret E; Birnbaum D; Moretta A; Olive D
Cancer Res; 2011 Nov; 71(21):6621-32. PubMed ID: 21937679
[TBL] [Abstract][Full Text] [Related]
20. A new molecular breast cancer subclass defined from a large scale real-time quantitative RT-PCR study.
Chanrion M; Fontaine H; Rodriguez C; Negre V; Bibeau F; Theillet C; Hénaut A; Darbon JM
BMC Cancer; 2007 Mar; 7():39. PubMed ID: 17338809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
